ReviewExpert opinion on drug metabolism & toxicology2008
The effect of chronic renal failure on drug metabolism and transport.
Review in Expert opinion on drug metabolism & toxicology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 1 synthesis or guideline pooled it, 243 citations in OpenAlex.
- Bioavailability, Efficacy and Safety of Generic Immunosuppressive Drugs for Kidney Transplantation: A Systematic Review and Meta-Analysis.American journal of nephrology · 2016Pooled it
- The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of mitiperstat.British journal of clinical pharmacology · 2024Trial
- Integrated Population Pharmacokinetics of Daprodustat in Patients with Chronic Kidney Disease with Anemia.Clinical pharmacokinetics · 2024Trial
- Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment.Clinical pharmacokinetics · 2022Trial
- Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease.Clinical journal of the American Society of Nephrology : CJASN · 2020Trial
- Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2YJournal of the American Heart Association · 2019Trial
- Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy.The pharmacogenomics journal · 2018Trial
- Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients.BMC pharmacology & toxicology · 2018Trial
- Efficacy of tolvaptan added to furosemide in heart failure patients with advanced kidney dysfunction: a pharmacokinetic and pharmacodynamic study.Clinical pharmacokinetics · 2015Trial
- Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.Antimicrobial agents and chemotherapy · 2014Trial
- Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study.Drug design, development and therapy · 2014Trial
- Effect of hepatic and renal impairment on the pharmacokinetics of dalcetrapib: altered distribution of the active thiol?Clinical pharmacokinetics · 2013Trial
- A Patient-Centered Approach for Drug-Drug Interaction (DDI) Assessment: Integrating Nested Clinical DDI Studies to Verify Translatability of Healthy Volunteer DDI Data, Minimize Stand-Alone Trials, and Enrich Drug Labeling.Clinical pharmacokinetics · 2026Review
- CYP2D6 as an Emerging Endogenous Oxidative Stress Modulator in Cardiovascular Disease: Genetic, Pharmacological, and Redox Perspectives.Antioxidants (Basel, Switzerland) · 2026Review
- Effect of kidney function on drug concentrations of first-line anti-tubercular treatment.Infection · 2026Article
- Mechanisms of Obesity-Related Kidney Disease: From Adipose Depot Biology to the Chymase-Aldosterone and Ghrelin-Leptin Axes.Biomolecules · 2026Review
- Metoprolol Population Pharmacokinetics in Older Chinese Patients With CKM Syndrome: Joint Effects of rs1065852 and CKMClinical and translational science · 2026Article
- Model-Based Virtual Clinical Trial Reveals Renal Impairment and Body Size as Key Determinants of Pharmacokinetic Variability and Drug-Drug Interaction Risk in Propranolol Therapy.Pharmaceutics · 2026Article
- Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib.British journal of clinical pharmacology · 2026Article
- Impact of chronic kidney disease stage on seizure frequency and severity in pediatric epilepsy patients.BMC nephrology · 2026Article
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundChronic renal failure (CRF) has been shown to significantly reduce the nonrenal clearance and alter bioavailability of drugs predominantly metabolized by the liver and intestine.
objectivesThe purpose of this article is to review all significant animal and clinical studies dealing with the effect of CRF on drug metabolism and transport.
methodsA search of the National Library of Medicine PubMed was done with terms such as chronic renal failure, cytochrome P450 [CYP], liver metabolism, efflux drug transport and uptake transport, including relevant articles back to 1969.
resultsAnimal studies in CRF have shown a significant downregulation (40-85%) of hepatic and intestinal CYP metabolism. High levels of parathyroid hormone, cytokines and uremic toxins have been shown to reduce CYP activity. Phase II reactions and drug transporters such as P-glycoprotein and organic anion transporting polypeptide are also affected.
conclusionCRF alters intestinal, renal and hepatic drug metabolism and transport producing a clinically significant impact on drug disposition and increasing the risk for adverse drug reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.